Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment

2018 ◽  
Vol 79 (3) ◽  
pp. AB83
Keyword(s):  
Cost Effectiveness ◽  
Severe Psoriasis ◽  
Biologic Drugs ◽  
Psoriasis Treatment ◽  
The Cost

Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States

2018 ◽  
Vol 29 (8) ◽  
pp. 769-774 ◽  
Author(s):  
Jashin J. Wu ◽  
Steven R. Feldman ◽  
Shipra Rastogi ◽  
Brandy Menges ◽  
Melissa Lingohr-Smith ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
The United States ◽  
Severe Psoriasis ◽  
Biologic Drugs ◽  
Psoriasis Treatment ◽  
The Cost

Evaluating Costs of Biologic Drugs for the Treatment of Moderate-to-Severe Psoriasis in the United States

2019 ◽  
Vol 4 (3) ◽  
pp. 133-142
Author(s):  
Steven R. Feldman ◽  
Jashin J. Wu ◽  
April W. Armstrong ◽  
Mark Lebwohl ◽  
Abby A. Jacobson ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Treatment Cost ◽  
Severity Index ◽  
The United States ◽  
Severe Psoriasis ◽  
Biologic Drugs ◽  
Annual Treatment ◽  
The Cost ◽  
Annual Treatment Cost

Objective:To provide a contemporary comparative assessment of biologic drug costs and cost effectiveness for treating moderate-to-severe psoriasis in the United States.Methods:A literature search was conducted in PubMed on October 4, 2018 with the search terms of “psoriasis,” “biologic,” and “cost” with a filter of publication dates within the last 5 years (2014-2018). Studies included in this review were required to be conducted from a United States perspective.Results:Of the 16 studies retrieved, the costs associated with use of biologic drugs for the treatment of moderate-to-severe psoriasis were relatively high, with some drugs exhibiting sustained lower costs than others. Some comparative findings on the cost-effectiveness of biologic drugs based on the annual treatment cost per Psoriasis Area and Severity Index (PASI) 75 responder concluded that the annual treatment cost was lowest for brodalumab 210 mg at US$48 782; the cost was highest for ustekinumab 45/90 mg (US$87 243), followed by adalimumab 40 mg (US$82 655), ixekizumab 160 mg (US$77 957), and secukinumab 300 mg (US$75 671). The annual treatment cost per PASI 100 responder was also lowest for brodalumab at US$87 585. This pattern remained consistent in other cost studies, with brodalumab being the treatment with the lowest treatment costs when compared to other biologic drugs.Conclusion:Brodalumab was consistently observed to be the least costly treatment option among biologic drugs used to treat moderate-to-severe psoriasis in the United States, which is largely the result of its low-drug cost and high-PASI response rate.

The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis

2015 ◽  
Vol 15 (6) ◽  
pp. 877-884 ◽  
Author(s):  
Nicole C. Rouse ◽  
Michael E. Farhangian ◽  
Brooke Wehausen ◽  
Steven R. Feldman
Keyword(s):  
Cost Effectiveness ◽  
Severe Psoriasis ◽  
The Cost

scholarly journals Economic Burden and Cost-Effectiveness of Moderate to Severe Psoriasis Treatment in Asian Region: A Systematic Review

2021 ◽  
Vol 7 (1) ◽  
pp. 196
Author(s):  
Nurul Fatiha Risma Rismayuddin ◽  
Nor Azmaniza Azizam ◽  
Aniza Ismail
Keyword(s):  
Systematic Review ◽  
Cost Effectiveness ◽  
Economic Burden ◽  
English Language ◽  
Cost Effective ◽  
The United States ◽  
Severe Psoriasis ◽  
Economic Effects ◽  
Asian Region ◽  
The Cost

Psoriasis poses a significant economic burden. A systematic review of psoriasis treatments cost and effectiveness has been performed extensively in the United States (US) and Europe, but such review is limited in Asia. This review aims to analyze all previous literature on the cost and effectiveness of systemic and biological treatment for moderate to severe psoriasis. Cost of illness and cost-effectiveness studies that examined the economic burden, cost, and effectiveness of psoriasis treatments (systemic and biological) in Asian region from 2010 to 2020 were published in English language. All costs were converted into 2020 US Dollar. All COIs included found that direct medical costs were greater than indirect costs. Adalimumab, ustekinumab, risankizumab, secukinumab 150 mg were cost-effective treatments and of the lowest cost per PASI-75/PASI1 and/or QALY. When comparing the different treatments, topical and systemic psoriasis treatments were observed to be the most cost-effective compared with other modalities. Given the tremendous economic effects of psoriasis on patients and hospitals, economic analysis, clinicians, and policymakers should consider cost and effectiveness evidence, as this systematic literature review was conducted to analyze previous documentation regarding the cost and effectiveness of systemics and biologics in Asian countries.

Sign in / Sign up

Export Citation Format

Share Document